July 31, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.1% Profit Achieved ~1 min.On April 16, 2025, QuantWave issued a short forecast signal for BRISTOL-MYERS SQUIBB COMPANY with a price of 48.72 $. Fast forward to July 31, 2025, the target price of 43....
July 31, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Forecast Price Target with 10.86% Profit ~1 min.QuantWave, an automated forecasting platform, recently achieved a milestone in its prediction accuracy with the successful forecast of BRISTOL-MYERS SQUIBB COMPANY's stock movement....
June 23, 2025Bristol Myers Squibb NYSE:BMY Set to Revolutionize Cancer Treatment with Breakthrough Drug ~1 min.Bristol Myers Squibb Company, a leading pharmaceutical company, is on the verge of revolutionizing cancer treatment with its groundbreaking new drug....
June 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu ~1 min.Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....
May 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit ~2 min.QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....
May 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin ~2 min.On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....
May 14, 2025BRISTOL-MYERS SQUIBB COMPANY Stock Hits Price Target with 9.09% Profit: QuantWave Forecast Success ~2 min.On April 23, 2025, QuantWave's forecasting platform generated a short signal for BRISTOL-MYERS SQUIBB COMPANY stock, which was trading at $47.9 at the time....
May 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 12.75% Profit - QuantWave Analysis ~1 min.BRISTOL-MYERS SQUIBB COMPANY recently achieved the price target forecast set by QuantWave, resulting in a profitable outcome of 12.75%....
May 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.87% Profit ~1 min.On May 5, 2025, QuantWave issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.41. The forecast proved accurate as the price target of $43....
May 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target Forecast with 11.76% Profit ~1 min.On April 15, 2025, QuantWave, the automated forecasting platform, issued a short signal for BRISTOL-MYERS SQUIBB COMPANY when the stock was trading at $49.35....
December 26, 2024Positive Results from Psoriatic Arthritis Trials Boost Bristol-Myers Squibb Stock ~1 min.Bristol-Myers Squibb Company (BMY), a leading pharmaceutical company, has recently announced positive topline results from two pivotal Phase 3 trials evaluating its drug Sotyktu deucravacitinib in adults with psoriatic arthritis. The trials have shown promising outcomes, with the drug meeting key endpoints and demonstrating effectiveness in treating the condition. Psoriatic arthritis is a chronic ...
February 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development ~1 min.Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....
December 29, 2024Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment ~1 min.Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have shown that Sotyktu hits key endpoints and provides positive outcomes for patients suffering from this debilitating condition. Institutional investors ...
March 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments ~1 min.Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....
January 5, 2025Regeneron Pharmaceuticals: A Strong Performer with Promising Financials ~2 min.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been a steady performer in the biopharmaceutical industry, delivering a decent return of 89% for investors over the last five years....
